

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/501,187
				Filing Date	January 8, 2003
				First Named Inventor	Rhonda HANSEN
				Art Unit	1635
				Examiner Name	T. C. Gibbs
Sheet	7	of	10	Attorney Docket Number	223002105200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear T <sup>6</sup>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	123.	KOROLCHUK, V. I. et al. (2002). "CK2 and GAK/Auxilin2 are Major Protein Kinases in Clathrin-Coated Vesicles," <i>Traffic</i> 3:428-439.		
	124.	KOSTELNY, S. A. et al. (March 1, 1992). "Formation of a Bispecific Antibody by the Use of Leucine Zippers," <i>Journal of Immunology</i> 148(5):1547-1553.		
	125.	KUTEMEIER, G. et al. (August 1994). "Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-Round PCR," <i>BioTechniques</i> 17(2):242-246.		
	126.	LIAUTARD, J. et al. (April 1997). "Specific Inhibition of IL-6 Signalling with Monoclonal Antibodies Against the gp130 Receptor," <i>Cytokine</i> 9(4):233-241.		
	127.	LOGAN, J. et al. (June 1984). "Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 81:3655-3659.		
	128.	LUO, L. et al. (January 1999). "Gene Expression Profiles of Laser-captured Adjacent Neuronal Subtypes," <i>Nature Medicine</i> 5(1):117-122.		
	129.	MASUI, A. et al. (October 1994). "Stabilization and Rational Design of Serine Protease AprM under Highly Alkaline and High-Temperature Conditions," <i>Applied and Environmental Microbiology</i> 60(10):3579-3584.		
	130.	MIKI, Y. et al. (October 7, 1994). "A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1," <i>Science</i> 266:66-71.		
	131.	MORRISON, S. J. et al. (March 5, 1999). "Prospective Identification, Isolation by Flow Cytometry, and In Vivo Self-Renewal of Multipotent Mammalian Neural Crest Stem Cells," <i>Cell</i> 96:737-749.		
	132.	MULLER, Y. A. et al. (September 15, 1998). "VEGF and the Fab Fragment of a Humanized Neutralizing Antibody: Crystal Structure of the Complex at 2.4 Å Resolution and Mutational Analysis of the Interface," <i>Structure</i> 6(9):1153-1167.		

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/501,187
				Filing Date	January 8, 2003
				First Named Inventor	Rhonda HANSEN
				Art Unit	1635
				Examiner Name	T. C. Gibbs
Sheet	8	of	10	Attorney Docket Number	223002105200

133.	NIWA, M. et al. (December 23, 1999). "A Role for Presenilin-1 in Nuclear Accumulation of Irf1 Fragments and Induction of the Mammalian Unfolded Protein Response," <i>Cell</i> 99:691-702.	
134.	OLSEN, O. et al. (1991). "Improvement of Bacterial $\beta$ -Glucanase Thermostability by Glycosylation," <i>Journal of General Microbiology</i> 137:579-585.	
135.	PAPPALARDO, P. A. et al. (July 1998). "Microdissection, Microchip Arrays, and Molecular Analysis of Tumor Cells (Primary and Metastases)," <i>Seminars in Radiation Oncology</i> 8(3):217-223.	
136.	Partial European Search Report mailed July 9, 2009, for EP Application No. 09156623.2 filed January 8, 2003, 3 pages.	
137.	PETERSEN, O. W. et al. (October 1992). "Interaction with Basement Membrane Serves to Rapidly Distinguish Growth and Differentiation Pattern of Normal and Malignant Human Breast Epithelial Cells," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 89:9064-9068.	
138.	PEYROTTE, S. et al. (1996). "Oligodeoxynucleoside Phosphoramidates (P-NH <sub>2</sub> ): Synthesis and Thermal Stability of Duplexes with DNA and RNA Targets," <i>Nucleic Acids Research</i> 24(10):1841-1848.	
139.	PHILIP, R. et al. (April 1994). "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Molecular and Cellular Biology</i> 14(4):2411-2418.	
140.	PITARD, V. et al. (1997). "Production and Characterization of Monoclonal Antibodies Against the Leukemia Inhibitory Factor Low Affinity Receptor, gp190," <i>Journal of Immunological Methods</i> 205(2):177-190.	
141.	POOGA, M. et al. (2001). "Targeting of Cancer-Related Proteins with PNA Oligomers," <i>Current Cancer Drug Targets</i> 1:231-239.	
142.	PRAT, M. et al. (1998). "Agonistic Monoclonal Antibodies Against the Met Receptor Dissect the Biological Responses to HGF," <i>Journal of Cell Science</i> 111:237-247.	
143.	QUEROL, E. et al. (1996). "Analysis of Protein Conformational Characteristics Related to Thermostability," <i>Protein Engineering</i> 9(3):265-271.	
144.	RAMSAY, G. (January 1998). "DNA Chips: State-of-the Art," <i>Nature Biotechnology</i> 16:40-44.	
145.	RUTHER, U. et al. (1983). "Easy Identification of cDNA Clones," <i>The EMBO Journal</i> 2(10):1791-1794.	
146.	SADHU, C. et al. (June 1987). "In Vitro Synthesis of Double Stranded RNA and Measurement of Thermal Stability: Effect of Base Composition, Formamide and Ionic Strength," <i>Biochemistry International</i> 14(6):1015-1022.	
147.	SAUERMAN, M. et al. (2008). "Reduced Expression of Vacuole Membrane Protein 1 Affects the Invasion Capacity of Tumor Cells," <i>Oncogene</i> 27:1320-1326.	
148.	SCHENA, M. et al. (October 1996). "Parallel Human Genome Analysis: Microarray-based Expression Monitoring of 1000 Genes," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 93:10614-10619.	
149.	SCHENA, M. et al. (October 20, 1995). "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray," <i>Science</i> 270:467-470.	
150.	SHALON, D. et al. (1996). "A DNA Microarray System for Analyzing Complex DNA Samples Using Two-Color Fluorescent Probe Hybridization," <i>Genome Research</i> 6:639-645.	
151.	SONNHAMMER, E. L. L. et al. (June 28-July 1, 1998). "A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences," <i>Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB-98)</i> , Montreal, Quebec, Canada, pp. 175-182.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/501,187
				Filing Date	January 8, 2003
				First Named Inventor	Rhonda HANSEN
				Art Unit	1635
				Examiner Name	T. C. Gibbs
Sheet	9	of	10	Attorney Docket Number	223002105200

152.	TUTT, A. et al. (July 1, 1991). "Trispecific F(ab') <sub>3</sub> Derivatives that Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells," <i>The Journal of Immunology</i> 147(1):60-69.	
153.	TWYMAN, R. E. et al. (April 1995). "Glutamate Receptor Antibodies Activate a Subset of Receptors and Reveal an Agonist Binding Site," <i>Neuron</i> 14:755-762.	
154.	United States Patent Application No. 09/872,850, filed June 1, 2001 for Suduth-Klinger et al.	
155.	United States Patent Application No. 10/616,900, filed July 9, 2003 for Suduth-Klinger et al.	
156.	VAN HEEKE, G. et al. (April 5, 1989). "Expression of Human Asparagine Synthetase in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> 264(10):5503-5509.	
157.	WAKARCHUK, W. W. et al. (November 1994). "Thermostabilization of the <i>Bacillus circulans</i> Xylanase by the Introduction of Disulfide Bonds," <i>Protein Engineering</i> 7(11):1379-1386.	
158.	WANG, F. et al (December 1998). "Reciprocal Interactions Between $\beta$ 1-Integrin and Epidermal Growth Factor Receptor in Three-Dimensional Basement Membrane Breast Cultures: A Different Perspective in Epithelial Biology," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 95:14821-14826.	
159.	WEAVER, V. M. et al. (April 7, 1997). "Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies," <i>The Journal of Cell Biology</i> 137(1):231-245.	
160.	WELLS, J. A. et al. (1985). "Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites," <i>Gene</i> 34:315-323.	
161.	WELLS, J. A. et al. (1986). "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin," <i>Philosophical Transactions of the Royal Society of London, Series A</i> , 317(2 and 3):415-423.	
162.	WIANNY, F. et al. (1998). "Mouse Polo-Like Kinase 1 Associates with the Acentriolar Spindle Poles, Meiotic Chromosomes and Spindle Midzone During Oocyte Maturation," <i>Chromosoma</i> 107:430-439.	
163.	WOFFENDIN, C. et al. (November 1994). "Nonviral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene into Primary Human T cells," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 91:11581-11585.	
164.	WU, C. H. et al. (October 15, 1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements In Vivo," <i>The Journal of Biological Chemistry</i> 264(29):16985-16987.	
165.	WU, G. Y. et al. (April 15, 1994). "Incorporation of Adenovirus into a Ligand-Based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," <i>The Journal of Biological Chemistry</i> 269(15):11542-11546.	
166.	WU, G. Y. et al. (August 5, 1991). "Receptor-Mediated Gene Delivery In Vivo. Partial Correction of Genetic Analbuminemia in Nagase Rats," <i>The Journal of Biological Chemistry</i> 266(22):14338-14342.	
167.	WU, G. Y. et al. (October 15, 1988). "Communication: Receptor-Mediated Gene Delivery and Expression In Vivo," <i>The Journal of Biological Chemistry</i> 263(29):14621-14624.	
168.	YOON, D.-Y. et al. (1998). "Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1 $\beta$ Activity But Not Binding: Regulation of IL-1 Responses Is Via Type I Receptor, Not the Accessory Protein," <i>The Journal of Immunology</i> 160:3170-3179.	
169.	ZERNICKA-GOETZ, M. et al. (1997). "Following Cell Fate in the Living Mouse Embryo," <i>Development</i> 124:1133-1137.	
170.	ZHU, Z. et al. (August 1, 1998). "Inhibition of Vascular Endothelial Growth Factor-Induced Receptor Activation with Anti-Kinase Insert Domain-Containing Receptor Single-Chain Antibodies from a Phage Display Library," <i>Cancer Research</i> 58:3209-3214.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/501,187
				Filing Date	January 8, 2003
				First Named Inventor	Rhonda HANSEN
				Art Unit	1635
				Examiner Name	T. C. Gibbs
Sheet	10	of	10	Attorney Docket Number	223002105200

	171.	ZOLLER, M. J. et al. (1982). "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA," <i>Nucleic Acids Research</i> 10(20):6487-6500.	
--	------	---	--

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.